Vienna, Austria, 06 February 2018 - Hookipa Biotech AG (“Hookipa”), a clinical stage biotech company pioneering an innovative class of immune activation therapies for oncology and infectious diseases, today announced that CEO Joern Aldag and CMO Igor Matushansky will be attending the LEERINK Partners 7th Annual Global Healthcare Conference at the Lotte New York Palace Hotel in New York, USA on Wednesday, February 14th and Thursday, February 15th, 2018.
Mr. Aldag and Dr. Matushansky will participate in a series of one-on-one meetings with select institutional investors to provide an overview of the company´s strategy as well as an update on its development programs, including progress on two proof-of concept clinical trials and plan to expand its technology platform into other disease areas.
About Hookipa Biotech
Hookipa Biotech is a clinical stage company developing next-generation immunotherapies for infectious diseases and cancer using novel proprietary arenavirus vector platforms.
Hookipa´s Vaxwave® technology presents a completely new replication-defective viral vector platform designed to overcome the limitations of current technologies. Vaxwave® is based on lymphocytic choriomeningitis virus (LCMV). In this vector the gene encoding the LCMV envelope protein, normally responsible for virus entry into target cells, has been deleted and replaced with an antigen of interest. The resulting vectors infect dendritic cells and stimulate very potent and long-lasting immune response, however they cannot replicate and are therefore non-pathogenic and inherently safe.
Hookipa’s TheraT® platform is based on an attenuated replicating arenavirus and is capable of eliciting the most potent T cell responses - a crucial step in treating patients with aggressive cancers. Significant pre-clinical data demonstrates that TheraT® is a powerful modality capable of turning “cold tumors hot” which should result in an additional layer of efficacy in the fight against solid tumors. Specifically, TheraT® has proven to be safe in animals as well as capable of eliciting uniquely potent antigen-specific CD8+ cytotoxic T cell responses and strong tumor control in mice. The first clinical trial with HB-201 targeting human papilloma virus-induced head and neck cancer is currently being prepared. This immuno-oncology technology is further being leveraged to target tumor self-antigens or shared neoantigens.
Issued for and on behalf of Hookipa Biotech AG by Instinctif Partners. For further information please contact:
At the Company
Hookipa Biotech AG
Sue Charles/ Ashley Tapp
+44 (0)20 7866 7923